Upbeat Assessment Of Onyx's Nexavar

An upbeat independent assessment of Onyx Pharmaceuticals Inc. (ONXX) and Bayer AG's (BAY) liver cancer drug Nexavar prompted the companies to halt a late stage clinical trial and begin offering the treatment to all patients involved in the study. Shares of Onyx leaped $3.42 to close at $37.04 while Bayer stock lost $1.48 to close at $76.78.